Teva Pharmaceutical Industries Limited Überblick
Branche: Drug Manufacturers—Specialty & Generic
Sektor: Healthcare
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency
Research-Überblick
Letztes Berichtsdatum 2026-07-29Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Teva Pharmaceutical Industries Limited (TEVJF): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.
- Börsennotierung
- TEVJF · OTC
- Land
- Israel
- Handelswährung
- USD
- Branche
- Drug Manufacturers—Specialty & Generic
- Finanzdaten
- Jahres- und Zwischenabschlüsse verfügbar
- Letzte Primärquelle
- SEC EDGAR · veröffentlicht 2026-07-29
- Letzter Bericht · SEC EDGAR Veröffentlicht 2026-07-29
- Registrierungsdokument
Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.
Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Teva Pharmaceutical Industries Limited für einen nachvollziehbaren Research-Prozess ein.
Score
Veröffentlichte Ergebnisse
Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.
Quarterly result summary
Revenue was $696M (+40% YoY); EPS was $0.02 (reported).
Was sich verändert hat
- Revenue +40% YoY to $696M; EPS reported to $0.02.
- Capital return update: free cash flow $622M.
- Net income -237% YoY to $283M.
Guidance / outlook
we expect our annual non-GAAP tax rate for 2026 to be between 20%-23%, higher than our non-GAAP tax rate for 2025, which was 15.8%.
Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.
Weitere aktuelle Ergebnisunterlagen
Geprüfte Signal-Evidenz
Aktuelle Nachrichten
Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.
What Is Teva Pharmaceutical Industries (TEVA) Gaining From This Bankruptcy Drug Deal?
Headline from Yahoo Finance: What Is Teva Pharmaceutical Industries (TEVA) Gaining From This Bankruptcy Drug Deal?
Teva Pharmaceutical Industries (TEVA) Could Be 11% Undervalued As FDA Accepts Ecopipam Filing
Headline from Yahoo Finance: Teva Pharmaceutical Industries (TEVA) Could Be 11% Undervalued As FDA Accepts Ecopipam Filing.
Teva (TEVA) Stock Looks Below Fair Value While Earnings Sit Above Fair Value
Headline from Yahoo Finance: Teva (TEVA) Stock Looks Below Fair Value While Earnings Sit Above Fair Value.
Teva Announces Proposed Acquisition of a Novel
Headline from GlobeNewswire: Teva Announces Proposed Acquisition of a Novel.
Teva receives FDA acceptance for ecopipam Tourette treatment NDA
Headline from Investing.com: Teva receives FDA acceptance for ecopipam Tourette treatment NDA.
Teva receives FDA acceptance for ecopipam Tourette treatment NDA By Investing.com
Headline from Investing.com South Africa: Teva receives FDA acceptance for ecopipam Tourette treatment NDA By Investing.com.
Gewinn je Aktie
Eigenkapitalrendite
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Nettomarge
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Verschuldung
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Finanzberichte
Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.
Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.